Thursday, 12 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

Antibe Therapeutics

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • Diabetes
  • SHA: 600276
Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB
CompanyDeals

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Fuzhou Luyan Pharmacy Co., Ltd. ("Luyan Pharma") signed an exclusive strategic cooperation agreement with Curae LAB, a subsidiary of the French GTH Group, for the Synergia brand in Greater China.…

November 12, 2026
Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

November 12, 2026
Amgen's Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren's Disease Activity

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

November 12, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics

October 20, 2024
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up